Avalo Therapeutics names Michael Heffernan as chair

Avalo Therapeutics ( NASDAQ: AVTX ) said it has appointed Michael Heffernan as the chair of the board. Heffernan will succeed Garry Neil in the role, and the latter will continue as the CEO of the company. Michael Heffernan has over 30 years of experience in the industry, and is the founder and chair of Collegium Pharmaceutical ( COLL ) More on Avalo Therapeutics Avalo climbs as Wedbush issues bullish view on lead asset Seeking Alpha’s Quant Rating on Avalo Therapeutics.